Background

About Uteron Pharma SA

Uteron Pharma is a pharmaceutical development company and part of Actavis, Inc.  Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.  Actavis is focused on enhancing its commercial position in global generics, brands and biologic pharmaceutical products, targeting products that will deliver long-term growth while maintaining a competitive cost structure.

Uteron Pharma is designated as one of Actavis’ Centre of Excellence for women’s healthcare delivering product development; cGMP manufacturing of hormonal intra-uterine devices (IUD) and quality/regulatory expertise from a custom-designed facility located in Liège, Belgium.

Uteron Pharma is active in four domains: Contraception & Fertility, Menopause & Osteoporosis, Vaginal infections and Oncology; and also operates a GMP approved 3,000 square meters production facility in Grâce-Hollogne (Belgium).

The company is currently developing a new generation of oral contraceptives based on natural estrogen, hormonal intra-uterine devices, an innovative diagnostic test to increase in vitro fertilization success rate and treatments for cervical dysplasia and recurrent vaginal infections.

About Actavis, Inc.

Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.

The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland.

• The new Actavis, Inc. is a powerful combination of the highly successful and previously separate Watson Pharmaceuticals, Inc. (NYSE:WPI) and privately-held, Swiss-based Actavis Group.
• Actavis is the world’s third-largest generic pharmaceutical company, with more than 750 molecules in 1,700 dosage combinations marketed globally through operations in more than 60 countries.
• Actavis’ branded pharmaceutical business, which operates under the name Actavis Specialty Brands, develops and markets products principally in Urology and Women’s Health.
• Actavis is committed to developing and marketing biosimilars products in Women’s Health, Oncology and other therapeutic categories.
• Actavis’ Anda, Inc., is the fourth-largest U.S. generic pharmaceutical product distributor.
• Actavis develops and out-licenses generic pharmaceutical products to customers in more than 100 countries outside of the U.S. through its Medis third-party business.

Actavis has manufacturing, R&D and commercial operations in more than 60 countries, with access to more than 5 billion of the world’s consumers.

Our commercial operations and facilities are strategically located around the world to maximize development opportunities, ensure an uninterrupted supply of product to market and provide industry-leading customer service.